Allogene Therapeutics, Inc. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets
Allogene Therapeutics, Inc. (ALLO) had Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets of $113.90 million as of 2018-04-30, per its 10-K filed 2021-02-25.
Discontinued › Notes › Business Combination, Recognized Asset Acquired, Asset
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets · last filed 2021-02-25
- 2018-04-30: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets $113.90M.
| Period end | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets |
|---|---|
| 2018-04-30 | $113.90M 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |